Comments on: From Clinic to Lab: How Reverse Pharmacology Is Proving Ayurveda

By: Jessica Reed

Jessica Reed — Thu, 11 Jun 2026 21:48:34 +0000

Given the high attrition rates in conventional drug development, reverse pharmacology could save resources by focusing on leads with human exposure.

Karen Phillips — Wed, 03 Jun 2026 09:09:00 +0000

It would be helpful to see more detail on how biomarker panels are selected for stratification in these studies.

Laura Mitchell — Mon, 25 May 2026 13:16:18 +0000

Seeing the mention of GCP-ASU makes me think about how ethical oversight is evolving for traditional medicine research.

Emily Foster — Sun, 17 May 2026 03:57:29 +0000

The article rightly points out that historical use is a lead, not a proof of efficacy.

Rebecca Turner — Fri, 08 May 2026 20:58:50 +0000

Standardizing therapist training for procedures like Basti seems essential to reduce bias in outcome measurement.

Susan Clark — Thu, 30 Apr 2026 06:21:21 +0000

I’m not convinced that observational work alone can replace controlled trials for safety assessment.

Rachel Adams — Tue, 21 Apr 2026 14:45:04 +0000

The discussion on Prakriti-based genomic work clarifies that dosha types aren’t yet clinical genetic tests.

Nicole Hayes — Mon, 13 Apr 2026 11:14:44 +0000

Reading about the CTRI registrations makes me curious about how many Ayurveda trials actually get posted there.

Jason Miller — Sat, 04 Apr 2026 16:01:54 +0000

One thing that stands out is the need for pharmacopeial standards for mineral-based preparations.

Chris Morgan — Fri, 27 Mar 2026 05:23:36 +0000

It’s interesting that the knee osteoarthritis trial includes both procedural and oral components as a package.